

U.S.S.N. 09/706,045

Filed: November 3, 2000

CLEAN VERSION OF AMENDED CLAIMS**Clean Version of Amended Claims
Pursuant to 37 C.F.R. § 1.121(c)(1)(ii)**

23. (Amended) A method of delivering a drug to a patient in need thereof, comprising administering a therapeutically or prophylactically effective amount of the drug in a formulation comprising a porous matrix which comprises a wetting agent and microparticles of the drug, wherein the microparticles have a mean diameter between about 0.1 and 5 μm and a total surface area greater than about 0.5 m^2/mL , and wherein the porous matrix has a TAP density less than or equal to 1.0 g/mL and/or has a total surface area of greater than or equal to 0.2 m^2/g and is in the form of a dry powder.

24. The method of claim 23 wherein the formulation is suitable for administration by a route selected from the group consisting of parenteral, mucosal, oral, and topical administration.

25. (Amended) The method of claim 24 wherein the parenteral route is selected from the group consisting of intravenous, intraarterial, intracardiac, intrathecal, intraosseous, intraarticular, intrasynovial, intracutaneous, subcutaneous, and intramuscular administration.

26. The method of claim 24 wherein the mucosal route is selected from the group consisting of pulmonary, buccal, sublingual, intranasal, rectal, and vaginal administration.

27. The method of claim 23 wherein the formulation is suitable for intraocular or conjunctival administration.

28. The method of claim 23 wherein the formulation is suitable for intracranial, intralesional, or intratumoral administration.

ATL: #535144v1

ACTJ 109 DIV (2)
0775R(000007)

U.S.S.N. 09/706,045

Filed: November 3, 2000

CLEAN VERSION OF AMENDED CLAIMS

B' Sub C6 cont

29. (Amended) The method of claim 23 wherein the formulation is suspended in an aqueous solution suitable for parenteral administration.

30. The method of claim 23 wherein the formulation is in a tablet or capsule suitable for oral administration.

31. The method of claim 23 wherein the formulation is in a suppository suitable for vaginal or rectal administration.

32. (Amended) The method of claim 23 wherein the formulation is suitable for pulmonary administration.

33. The method of claim 23 wherein the dry powder form of the porous matrix has a TAP density less than or equal to 1.0 g/mL.

34. The method of claim 23 wherein the dry powder form of the porous matrix has a total surface area of greater than or equal to 0.2 m²/g.

35. The method of claim 23 wherein the mean diameter of the microparticles is between about 0.5 and 5 μ m.

ATL1 #656144 v1

ATL1 #535144 v1